. Author manuscript; available in PMC: 2017 May 26.

Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 5;75:45–53. doi: 10.1016/j.pnpbp.2017.01.001

Table 2.

Summary of results from random-effects meta-analysis for all cognitive subdomains across all drug doses studied.

Cognitive subdomain	Effect size (95% CI)	I² (p-value)	Number of studies included
Overall cognitive index	−0.057 (−0.16, 0.044)	0 (0.72)	13
Attention	−0.077 (−0.20, 0.047)	0 (0.65)	14
Working memory	−0.011 (−0.14, 0.12)	3 (0.42)	14
Executive function	0.006 (−0.18, 0.19)	32 (0.16)	9
Speed of processing	−0.015 (−0.14, 0.11)	0 (0.98)	13
Verbal learning	−0.076 (−0.25, 0.096)	16 (0.30)	9
Visual learning	−0.048 (−0.19, 0.092)	0 (0.57)	11
Social cognition	0.031 (−0.15, 0.21)	0 (0.95)	5
Language	0.12 (−0.49, 0.72)	0 (0.38)	2

Note: negative effect size favors drug.